Sleep-Related Breathing Disorders

SECTION 1

Historical Context & Motivation

The recognition that disordered breathing during sleep constitutes a distinct clinical entity evolved gradually over the course of the twentieth century. For millennia, heavy snoring and daytime somnolence were dismissed as mere nuisances rather than signs of a pathological process. The pivotal shift occurred when clinicians began correlating nocturnal respiratory events with cardiovascular morbidity, neurocognitive impairment, and excess mortality. Today, sleep-related breathing disorders (SRBDs) represent one of the most prevalent and undertreated categories of disease encountered across primary care, pulmonology, and cardiology, with direct relevance to perioperative risk stratification, resistant hypertension workup, and long-term cardiovascular outcomes.

1956

The Pickwickian Syndrome

Burwell and colleagues described the "Pickwickian syndrome"—obesity, hypersomnolence, and alveolar hypoventilation—linking body habitus to disordered breathing during sleep for the first time in the medical literature.

1965

First Polysomnographic Studies

Gastaut, Tassinari, and Duron performed overnight polysomnography on obese patients, documenting repetitive upper-airway occlusion events and associated oxygen desaturations during sleep.

1981

Introduction of CPAP

Colin Sullivan in Sydney, Australia, demonstrated that continuous positive airway pressure (CPAP) delivered via a nasal mask could splint the upper airway open, revolutionizing the treatment of obstructive sleep apnea.

1993

Wisconsin Sleep Cohort

The landmark Wisconsin Sleep Cohort Study established population-level prevalence estimates, reporting that approximately 4% of men and 2% of women in middle age have symptomatic obstructive sleep apnea, and demonstrated its association with hypertension.

2014

ICSD-3 Classification

The International Classification of Sleep Disorders, Third Edition (ICSD-3), formally categorized SRBDs into obstructive sleep apnea syndromes, central sleep apnea syndromes, and sleep-related hypoventilation/hypoxemia disorders, providing the modern diagnostic framework.

Despite these advances, epidemiological data suggest that a majority of individuals with clinically significant sleep apnea remain undiagnosed. The central clinical question driving this topic is: how do we systematically identify, classify, and manage the spectrum of breathing abnormalities during sleep so that we can reduce downstream cardiovascular, metabolic, and neurocognitive sequelae? Answering this question requires a firm grasp of upper-airway physiology, the pathophysiology of ventilatory control, diagnostic polysomnographic criteria, and evidence-based treatment algorithms—all of which are high-yield for USMLE Step 2.

SECTION 2

Core Principles & Definitions

Before diving into specific disorders, it is essential to establish the foundational terminology and physiologic principles that underpin the entire SRBD spectrum. Apnea is defined as a complete cessation of airflow lasting ≥ 10 seconds, whereas hypopnea refers to a ≥ 30% reduction in airflow for ≥ 10 seconds accompanied by either a ≥ 3% oxygen desaturation or an arousal. The apnea-hypopnea index (AHI) quantifies the number of apneas plus hypopneas per hour of sleep and serves as the primary metric for diagnosing and grading severity of obstructive sleep apnea. These definitions, standardized by the American Academy of Sleep Medicine (AASM), allow clinicians to speak a common diagnostic language.

Obstructive Sleep Apnea (OSA)

Repetitive pharyngeal collapse during sleep despite ongoing respiratory effort. The hallmark is the presence of thoracoabdominal movement against an occluded airway. AHI ≥ 5 events/hour with symptoms, or AHI ≥ 15 regardless of symptoms.

Central Sleep Apnea (CSA)

Cessation of airflow due to absent respiratory effort, reflecting dysfunction of the brainstem ventilatory control center or instability in the chemoreflex feedback loop. Commonly seen in heart failure (Cheyne-Stokes respiration), opioid use, and high-altitude settings.

Obesity Hypoventilation Syndrome (OHS)

Defined by the triad of obesity (BMI ≥ 30 kg/m²), daytime hypercapnia (PaCO₂ ≥ 45 mmHg), and sleep-disordered breathing after exclusion of other causes of hypoventilation. Approximately 90% of OHS patients also have coexisting OSA.

Upper Airway Resistance Syndrome (UARS)

Increased respiratory effort leading to arousals without meeting formal criteria for apneas or hypopneas. Patients present with excessive daytime sleepiness and fragmented sleep despite a normal or near-normal AHI, but demonstrate elevated respiratory effort-related arousals (RERAs).

Apnea-Hypopnea Index (AHI) Severity Grading

Mild OSA: AHI 5–14; Moderate OSA: AHI 15–29; Severe OSA: AHI ≥ 30. The AHI, while the cornerstone metric, should be interpreted alongside symptom burden, oxygen nadir, and comorbidity profile for treatment decision-making.

✦ KEY TAKEAWAY

Think of the upper airway during sleep as a flexible rubber hose. In obstructive sleep apnea, the pump (diaphragm) is working, but the hose collapses because the walls are too floppy or the surrounding tissue compresses it. In central sleep apnea, the hose is patent, but the pump simply stops cycling because the brain's control signal is intermittent. In obesity hypoventilation syndrome, the pump is working against such heavy mechanical loading that it cannot generate adequate tidal volumes, leading to chronic CO₂ retention.

SECTION 3

Visual Explanation — Pathophysiology of Airway Obstruction

This diagram contrasts the three states of the upper airway during sleep. In the normal airway, the pharyngeal lumen remains patent and airflow is maintained. In obstructive apnea, the soft palate and tongue collapse posteriorly, obliterating the lumen despite persistent thoracoabdominal effort. In central apnea, the airway remains structurally open but the brainstem fails to generate respiratory drive, so no effort or airflow occurs.

The fundamental pathophysiologic distinction between obstructive and central apnea hinges on the presence or absence of respiratory effort during the cessation of airflow. In obstructive events, the diaphragm contracts against a closed upper airway, generating increasingly negative intrathoracic pressure swings that can be detected on esophageal manometry or inferred from thoracoabdominal belt paradoxical motion on polysomnography. In central events, both airflow and effort channels become flat simultaneously, indicating a failure of ventilatory drive originating from the medullary respiratory centers. A practical clinical implication of this distinction is that CPAP is effective for OSA because it pneumatically splints the collapsible segment, whereas central apnea may require adaptive servo-ventilation (ASV), supplemental oxygen, or treatment of the underlying cause such as heart failure optimization.

SECTION 4

Pathophysiologic Mechanisms & Diagnostic Metrics

The pathophysiology of OSA can be conceptualized through the Starling resistor model of the upper airway. The pharynx behaves as a collapsible tube whose patency depends on the balance between intraluminal pressure and the surrounding tissue pressure. The critical closing pressure (Pcrit) is the extraluminal pressure at which the airway collapses; patients with OSA have a higher (less negative) Pcrit than normal controls, meaning their airways close more easily. Four key pathophysiologic traits—often referred to as the "PALM" traits (Pcrit, Arousal threshold, Loop gain, Muscle responsiveness)—interact to determine an individual's susceptibility to OSA.

APNEA-HYPOPNEA INDEX

AHI = (Total Apneas + Total Hypopneas) ÷ Total Sleep Time (hours)

AHI is the primary severity metric: Mild = 5–14, Moderate = 15–29, Severe ≥ 30. Total sleep time is derived from PSG scoring—time in bed is not equivalent to total sleep time.

OXYGEN DESATURATION INDEX

ODI = Number of ≥ 3% (or ≥ 4%) SpO₂ drops ÷ Total Sleep Time (hours)

The ODI complements the AHI by quantifying the hypoxic burden of sleep-disordered breathing. An ODI ≥ 5 on home sleep testing, in appropriate clinical context, supports an OSA diagnosis even without formal PSG-derived AHI.

Ventilatory Control Instability in Central Sleep Apnea

Central sleep apnea results from instability in the negative-feedback loop governing ventilation. The concept of loop gain is critical here. Loop gain describes the magnitude of the ventilatory response to a given perturbation in PaCO₂. A high loop gain means that even a small decrease in PaCO₂ below the apneic threshold will trigger a central apnea. In congestive heart failure, prolonged circulatory time delays chemoreceptor feedback, further destabilizing the loop and producing the classic Cheyne-Stokes respiration pattern—a crescendo-decrescendo tidal volume oscillation interspersed with central apneas. Opioids, in contrast, cause CSA through direct suppression of medullary respiratory neurons, often with an irregular, ataxic breathing pattern rather than the rhythmic periodicity of Cheyne-Stokes.

LOOP GAIN CONCEPT

Loop Gain = Ventilatory Response ÷ Ventilatory Disturbance

Loop gain > 1 indicates an unstable system where the corrective response overshoots the disturbance, driving PaCO₂ below the apneic threshold and triggering a central apnea. Lower loop gain reflects a more stable system less prone to periodic breathing.

SECTION 5

Classification & Diagnostic Approach

This flowchart illustrates the stepwise diagnostic approach from clinical suspicion through screening, diagnostic testing, event classification, and initial management. Note that HSAT is appropriate for uncomplicated suspected OSA in patients without significant cardiopulmonary comorbidity, whereas in-laboratory PSG is required when central apnea, hypoventilation, or parasomnias are suspected.

Comparison of In-Lab Polysomnography and Home Sleep Apnea Testing

Feature	In-Lab PSG	Home Sleep Apnea Test (HSAT)
Channels monitored	EEG, EOG, EMG, ECG, airflow, effort belts, SpO₂, body position, leg EMG	Typically airflow, effort, SpO₂ ± body position (minimum Type III device)
Sleep staging	Yes — allows true AHI (events/hour of sleep)	No — reports REI (events/hour of recording time), which may underestimate severity
Best indication	Suspected CSA, hypoventilation, parasomnias, or when HSAT is negative but suspicion remains high	Uncomplicated suspected moderate-to-severe OSA in patients without major comorbidities
Limitations	Expensive, limited availability, "first-night effect" may alter sleep architecture	Cannot detect central apneas reliably, no EEG for arousal scoring, data loss from lead disconnection

⚡ HIGH-YIELD PEARL

The STOP-BANG questionnaire is the most commonly tested screening tool: Snoring, Tiredness, Observed apneas, high blood Pressure, BMI > 35, Age > 50, Neck circumference > 40 cm, male Gender. A score ≥ 3 has high sensitivity for moderate-to-severe OSA and should prompt diagnostic testing.

SECTION 6

Worked Example — Clinical Case Analysis

A 52-year-old man with a BMI of 38 kg/m², hypertension on three medications, and type 2 diabetes presents to his primary care physician with a chief complaint of excessive daytime sleepiness (Epworth Sleepiness Scale score of 16/24). His bed partner reports loud snoring with witnessed apneic episodes several nights per week. He has no history of heart failure, neuromuscular disease, or opioid use. How should this patient be evaluated and managed?

Clinical Case: Evaluation and Management of Suspected OSA

Step 1 — Assess Pre-Test ProbabilityApply the STOP-BANG questionnaire: Snoring (yes), Tiredness (yes, ESS 16), Observed apneas (yes), high blood Pressure (yes), BMI > 35 (yes, 38), Age > 50 (yes, 52), Neck circumference (assume > 40 cm in an obese male), male Gender (yes). STOP-BANG score = 7–8, indicating high probability of moderate-to-severe OSA.

STOP-BANG ≥ 5 → high pre-test probability

Step 2 — Select Diagnostic TestThis patient has no features suggesting central sleep apnea (no heart failure, no opioid use) and no suspicion for hypoventilation syndromes or parasomnias. He is a candidate for home sleep apnea testing (HSAT) as the initial diagnostic study. If HSAT is negative or inconclusive despite high clinical suspicion, in-laboratory PSG would be the next step.

HSAT appropriate as initial test

Step 3 — Interpret ResultsThe HSAT returns a respiratory event index (REI) of 42 events/hour with an oxygen nadir of 74%. Because HSAT uses recording time rather than actual sleep time as the denominator, the true AHI may be even higher. An REI of 42 qualifies as severe obstructive sleep apnea (≥ 30 events/hour). The oxygen nadir of 74% indicates significant hypoxic burden.

Severe OSA confirmed (REI 42, SpO₂ nadir 74%)

Step 4 — Initiate TreatmentFirst-line therapy for moderate-to-severe OSA is continuous positive airway pressure (CPAP). The patient should be fitted with a CPAP mask interface (nasal, nasal pillows, or oronasal) and a pressure titration should be performed—either via in-lab titration PSG or auto-titrating CPAP (APAP) at home. Given his obesity, concurrent counseling on weight management (targeting ≥ 10% body weight reduction), positional therapy if events are position-dependent, and consideration of bariatric surgery referral are important adjuncts.

CPAP initiated + weight management counseling

Step 5 — Assess for Comorbid OHSGiven his BMI of 38 and severe OSA, an arterial blood gas should be obtained to rule out obesity hypoventilation syndrome. If PaCO₂ ≥ 45 mmHg on daytime ABG (and serum bicarbonate is elevated, suggesting chronic compensation), the diagnosis of OHS is established. These patients may require bilevel PAP (BiPAP) rather than CPAP alone to augment ventilation and correct hypercapnia.

Check ABG → if PaCO₂ ≥ 45 mmHg → OHS → consider BiPAP

SECTION 7

Treatment Modalities — Comparison & Limitations

Summary of Major Treatment Modalities for Sleep-Related Breathing Disorders

Treatment	Mechanism / Indication	Limitations / Adverse Effects
CPAP	Pneumatic splint of the upper airway; first-line for all severities of OSA. Reduces AHI to < 5 in most patients when adherent.	Adherence is the major barrier (only ~50% use CPAP ≥ 4 hr/night). Side effects include mask discomfort, nasal congestion, aerophagia, and claustrophobia.
BiPAP	Provides inspiratory and expiratory pressure support; indicated for OHS, CPAP intolerance, or patients requiring higher pressures.	More expensive; may worsen central apneas in some patients if backup rate is not appropriately set.
Mandibular Advancement Device (MAD)	Oral appliance that protrudes the mandible, increasing retropalatal and retroglossal airway dimensions. Second-line for mild-moderate OSA or CPAP-intolerant patients.	Less effective than CPAP (AHI reduction ~50% vs ~90%). Temporomandibular joint pain, dental malocclusion with long-term use.
Hypoglossal Nerve Stimulator	Implanted device that stimulates cranial nerve XII during inspiration, protruding the tongue. For moderate-severe OSA with CPAP failure and BMI < 35.	Requires drug-induced sleep endoscopy (DISE) to exclude complete concentric collapse. Surgical implantation risks; not effective for all collapse patterns.
Adaptive Servo-Ventilation (ASV)	Delivers variable pressure support that decreases during hyperventilation and increases during hypoventilation, stabilizing the loop gain. First-line for treatment-emergent central apnea and some CSA subtypes.	CONTRAINDICATED in CSA with symptomatic HFrEF (LVEF ≤ 45%) based on the SERVE-HF trial, which showed increased cardiovascular mortality in this population.
Weight Loss / Bariatric Surgery	Addresses the primary risk factor; 10% weight loss reduces AHI by ~26%. Bariatric surgery may achieve OSA remission in a substantial proportion of morbidly obese patients.	Weight loss alone is insufficient for severe OSA acutely; must be paired with PAP. Surgical candidacy criteria must be met; weight regain is common.

⚠️ CRITICAL BOARD PEARL

The SERVE-HF trial is a commonly tested landmark study. ASV is contraindicated in patients with CSA and heart failure with reduced ejection fraction (LVEF ≤ 45%) because it was associated with increased all-cause and cardiovascular mortality. For these patients, the primary treatment is optimization of guideline-directed medical therapy for heart failure, which often reduces central apnea burden. Think of it this way: in HFrEF, Cheyne-Stokes respiration is a symptom of the failing heart, not a disease to treat with a ventilator—fix the pump, and the breathing pattern often improves.

SECTION 8

Complications & Connections to Advanced Concepts

Untreated sleep-related breathing disorders have far-reaching systemic consequences that extend well beyond daytime somnolence. The repetitive cycles of hypoxia-reoxygenation trigger intermittent hypoxia, which functions analogously to ischemia-reperfusion injury, generating reactive oxygen species, activating NF-κB-mediated inflammatory pathways, and promoting endothelial dysfunction. This mechanism links OSA to accelerated atherosclerosis, resistant hypertension, atrial fibrillation, stroke, and heart failure progression—conditions that are all high-yield associations for Step 2.

Systemic Complications of Untreated Sleep-Related Breathing Disorders

Complication Domain	Key Associations with Untreated OSA	Clinical Significance / Board Relevance
Cardiovascular	Resistant hypertension, atrial fibrillation, pulmonary hypertension, cor pulmonale, sudden cardiac death (nocturnal)	OSA is the most common identifiable cause of resistant hypertension. Screen all patients with HTN on ≥ 3 medications.
Metabolic	Insulin resistance, metabolic syndrome, NAFLD, impaired glucose tolerance	Intermittent hypoxia independently worsens insulin sensitivity, creating a bidirectional relationship between OSA and type 2 diabetes.
Neurocognitive	Excessive daytime sleepiness, impaired concentration, depression, increased motor vehicle accident risk	Patients with untreated moderate-severe OSA have a 2–7× increased risk of MVAs. Physicians may have a duty-to-warn obligation depending on jurisdiction.
Perioperative	Increased risk of difficult intubation, postoperative respiratory depression, atelectasis, ICU admission	Preoperative screening with STOP-BANG is recommended. Patients with known OSA should bring their CPAP to the hospital for perioperative use.
Hematologic	Secondary polycythemia from chronic intermittent hypoxia	Erythrocytosis in an obese patient should prompt evaluation for OSA/OHS as the underlying hypoxic stimulus.

Looking forward, emerging research is investigating the role of endotyping and phenotyping in OSA management—classifying patients by their dominant pathophysiologic trait (anatomic compromise, low arousal threshold, high loop gain, or poor muscle responsiveness) to guide personalized therapy. The concept of hypoxic burden as a metric beyond AHI is also gaining traction, as it may better predict cardiovascular outcomes. Additionally, pharmacologic approaches targeting arousal threshold modulation (e.g., eszopiclone) and upper-airway dilator muscle function (e.g., combination desipramine-ondansetron or the recently studied tirzepatide for weight reduction) represent the frontier of non-PAP therapeutic strategies. For Step 2, the key takeaway is that SRBD management is evolving from a one-size-fits-all CPAP approach toward precision medicine.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A polysomnogram demonstrates repeated episodes of absent airflow lasting 15–25 seconds. During these episodes, thoracoabdominal effort belts show persistent paradoxical movement. What type of apnea is this, and what is the underlying mechanism?

PROBLEM 2 — BASIC CALCULATION

A patient undergoes an overnight polysomnogram with a total sleep time of 6 hours. The study documents 48 obstructive apneas and 72 hypopneas. Calculate the AHI and classify the severity.

PROBLEM 3 — INTERMEDIATE

A 65-year-old woman with NYHA Class III heart failure (LVEF 30%) undergoes polysomnography showing a crescendo-decrescendo breathing pattern with central apneas, an AHI of 35, and > 50% central events. What is the diagnosis, and what treatment is contraindicated?

PROBLEM 4 — APPLIED

A 48-year-old man with a BMI of 44 kg/m² is referred for preoperative evaluation before elective cholecystectomy. He reports snoring and morning headaches. His serum bicarbonate is 32 mEq/L. An ABG shows pH 7.37, PaCO₂ 52 mmHg, PaO₂ 62 mmHg. A home sleep study reveals an REI of 55 events/hour. What diagnoses should be established, and how does this change perioperative management?

PROBLEM 5 — CRITICAL THINKING

A 60-year-old man with severe OSA is initiated on CPAP therapy. At his one-month follow-up, he reports persistent excessive daytime sleepiness despite CPAP adherence data showing usage of 6.5 hours/night with a residual AHI of 2 events/hour. What differential diagnoses should be considered for his persistent somnolence, and what next steps are appropriate?

SUMMARY

Summary

Sleep-related breathing disorders encompass a spectrum from obstructive sleep apnea (pharyngeal collapse with preserved effort) to central sleep apnea (absent ventilatory drive with a patent airway) to obesity hypoventilation syndrome (chronic daytime hypercapnia in the setting of obesity and sleep-disordered breathing). The apnea-hypopnea index (AHI) is the cornerstone diagnostic metric, with severity graded as mild (5–14), moderate (15–29), and severe (≥ 30). Diagnosis relies on polysomnography or home sleep apnea testing, with the choice dependent on clinical context and pre-test probability.

First-line treatment for OSA is continuous positive airway pressure (CPAP); alternatives include mandibular advancement devices and hypoglossal nerve stimulation. For CSA with HFrEF, ASV is contraindicated (SERVE-HF trial); instead, optimize heart failure medical therapy. OHS requires BiPAP and weight management. The systemic consequences of untreated SRBDs—resistant hypertension, atrial fibrillation, metabolic syndrome, neurocognitive impairment, and perioperative risk—make early identification and treatment a high-value clinical intervention and a high-yield topic for board examinations.